Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy.
about
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatmentCentral serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.A Preliminary Examination of the Relationship Between the 5-HTTLPR and Childhood Emotional Abuse on Depressive Symptoms in 10-12-Year-Old Youth.Antidepressant response and the serotonin transporter gene-linked polymorphic regionPharmacogenetics of antidepressant response.Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetineUnderstanding the pharmacogenetics of selective serotonin reuptake inhibitors.The dawn of pediatric personalized therapeuticsSerotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.Personalized medicine in psychiatry: problems and promises.Pharmacogenetics of antidepressantsPolymorphism in the serotonin receptor 2a (HTR2A) gene as possible predisposal factor for aggressive traits.The promise and reality of pharmacogenetics in psychiatryMonoamine transporters: vulnerable and vital doorkeepers.Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics.Major depressive disorder: new clinical, neurobiological, and treatment perspectives.Genetic Variations in the Serotonergic System Mediate a Combined, Weakened Response to SSRI Treatment: A Proposed Model(1,2)Pharmacogenetics of antidepressant response: an updateRole of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors.Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model.Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.Serotonin and brain function: a tale of two receptorsPharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence.Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine.Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study.Striatal N-acetylaspartate synthetase Shati/Nat8l regulates depression-like behaviors via mGluR3-mediated serotonergic suppression in mice.Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.Differences and similarities in the serotonergic diathesis for suicide attempts and mood disorders: a 22-year longitudinal gene-environment study.Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.Imaging genetics: implications for research on variable antidepressant drug response.Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder.Value of Supportive Care Pharmacogenomics in Oncology Practice.
P2860
Q26741187-660DB5A2-D640-44C1-BCE2-EBB66C155395Q27015830-E4D55412-DDE7-4364-8FCE-291AC3CAFA52Q28080944-D7A0BDAA-4A58-4F3E-8D94-EF535F4DBD42Q33654737-D9C3B2B0-36AD-4F07-9488-030892B8ACA1Q33753128-757EA2F3-9F5B-419C-BE25-29456FEFD624Q34088515-639BE87E-49FF-41B1-AFA4-46B578BCB99CQ34155796-8956F693-6ADB-4A00-9D7F-935D6F797DA8Q34256005-19567CE8-B6B6-4EA9-A774-9E9B3618C66CQ34424865-996F7343-FDA5-40A3-BE3A-BFE59E3BD8B5Q34473137-D25DBF66-B331-4E79-8089-076A19616F2CQ34473840-F63228CC-C817-4D01-A467-0C498A78C9F1Q34726454-26B5B6D2-0146-499D-BC3F-AB4DB80DB6EDQ35026088-FC9B32EA-2DBA-4409-8C15-9BA9A2856C25Q35058108-F97764AB-7F8A-4D92-81E6-7ACA66DD48F8Q35226451-3F2A7A9E-E8B2-46F4-97E8-FE00F384F336Q35877150-4CF36821-4551-4985-9F88-D9F8E92BCD4BQ36079358-6D668DE5-7A9D-4394-A60B-6AEB0F9D24E8Q36096664-5756FEA5-FD5F-48DB-A198-E8420E7D9A9DQ36103263-EA94DE56-FC11-4425-8F9C-08BB65669D1CQ37464458-D0B4FA38-B8D0-41AA-9DEF-DCF7A785608AQ37602790-31424496-1C25-4D03-A236-40CE5D3E87D6Q37669003-BF67DC7E-2B53-43F5-B44A-BC54AB341675Q37981722-A4A4A43B-26FF-4415-AFC2-7BDEAE3A106CQ37989490-3C8A1E51-AE29-436B-B1A7-1E101492A23AQ38081485-A1653643-F63A-4646-8FB2-2360EC7382BCQ38121519-C990E8DA-5000-4CC7-B470-74D63CE0ECFEQ38154911-99D00DBD-6942-4721-AE8D-8AEFEA68275AQ38600048-C08F1AA2-4812-48B4-9406-D658147DAE74Q38983579-5AC886F7-ED65-4009-BF10-46B4CA0EB436Q39400564-1375DFE4-7B70-4944-AB68-86EF422C04D9Q39820068-58A2FEDC-4D24-4495-B428-DF35331566B1Q40149970-D68CE2B3-134E-4653-83DD-4AFF02151B14Q41918980-4741F923-F6BE-4708-80AC-6A4E60E6E9D2Q44220312-91087382-A6D1-4F20-A2EE-C1D6F9CC12B2Q45902720-14C4205A-21D2-4E55-B5E3-977463619801Q46043540-3E8671B8-1228-42B9-9266-1C11CD0457C5Q46434348-30446B3B-8160-476B-AAB0-356A5A5FDC75Q48148747-2FD3A856-40F5-4D6D-BED7-630B3F6B26C2Q48267690-351A69AB-7CAC-4BFA-A854-D8EA81238829Q52603826-B05AC218-AB34-4671-8F67-C755F7409F5C
P2860
Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Polymorphisms in the SLC6A4 an ...... lowing antidepressant therapy.
@en
Polymorphisms in the SLC6A4 an ...... lowing antidepressant therapy.
@nl
type
label
Polymorphisms in the SLC6A4 an ...... lowing antidepressant therapy.
@en
Polymorphisms in the SLC6A4 an ...... lowing antidepressant therapy.
@nl
prefLabel
Polymorphisms in the SLC6A4 an ...... lowing antidepressant therapy.
@en
Polymorphisms in the SLC6A4 an ...... lowing antidepressant therapy.
@nl
P2093
P2860
P50
P356
P1476
Polymorphisms in the SLC6A4 an ...... lowing antidepressant therapy.
@en
P2093
P2860
P2888
P356
10.1038/SJ.TPJ.6500491
P577
2008-02-05T00:00:00Z